



## Liquidia to Present at the 2020 Webbush PacGrow Healthcare Virtual Conference

August 5, 2020

RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that Neal Fowler, Chief Executive Officer of Liquidia, will present a company overview at the 2020 Webbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 10:20am Eastern time.

A link to the live audio webcast and replay of the presentation will be available on the [Events & Presentations](#) page of the Company's corporate website, and will be archived for a minimum of 90 days.

### About Liquidia

Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. Liquidia is headquartered in Research Triangle Park, NC. For more information, please visit [www.liquidia.com](http://www.liquidia.com).

### Contact Information

#### Investor Relations:

Jason Adair

Vice President, Corporate Development and Strategy

919.328.4400

[jason.adair@liquidia.com](mailto:jason.adair@liquidia.com)



Source: Liquidia Technologies, Inc.